HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TAK
Takeda Pharmaceutical Company Limited
TAK lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TAK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
TAK's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TAK PE Valuation
TAK has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TAK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TAK's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
TAK has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus TAK up 83%.
TAK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.35 | +30% |
| Q2 2025 | $0.27 | -6.9% |
| Q1 2025 | $0.21 | -28% |
| Q4 2024 | $0.41 | +17% |
| Q3 2024 | $0.57 | +50% |
| Q2 2024 | $0.29 | -52% |
| Q1 2024 | $0.29 | -54% |
| Q4 2023 | $0.35 | -36% |
TAK earned $0.75 per share over the past year, up 83% from the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TAK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TAK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.4B | +6.7% |
| Q2 2026 | $7.6B | +10% |
| Q1 2026 | $7B | +5.8% |
| Q4 2025 | $7.6B | +6% |
| Q3 2025 | $7B | -5.4% |
| Q2 2025 | $6.9B | -8.4% |
| Q1 2025 | $6.6B | +0.2% |
| Q4 2024 | $7.2B | +3% |
TAK's revenue has grown year over year for four quarters in a row: $7.4B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +11 points |
| Q2 2026 | 17% | N/A |
| Q1 2026 | 4.3% | -12 points |
| Q4 2025 | 16% | +23 points |
| Q3 2025 | 6.2% | +0.4 points |
| Q2 2025 | 17% | +2.9 points |
| Q1 2025 | -7.1% | -6.2 points |
| Q4 2024 | 5.8% | -3.6 points |
TAK has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TAK on cash flow, with more consistent year-over-year improvement.
TAK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $462.7M | -47% |
| Q1 2026 | $63.5M | -92% |
| Q4 2025 | $945.7M | -54% |
| Q3 2025 | $2B | +73% |
| Q2 2025 | $879.7M | +735% |
| Q2 2025 | $879.7M | +735% |
| Q1 2025 | $811.3M | -40% |
| Q4 2024 | $2.1B | +372% |
TAK still generates free cash flow, though less than at its 2022 peak: $3.5B over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TAK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TAK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +1.7% | +54.5M shares |
| 3 years | +2.5% | +78.8M shares |
| 5 years | +1.5% | +48.6M shares |
| Available history | +3% | +94M shares |
TAK has 3.2B diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $6.3M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $323.4M |
| Q1 2025 | $313.3M |
| Q4 2024 | — |
| Q3 2024 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TAK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.5x | Elevated |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 3.6x | Elevated |
| Q4 2024 | 3.6x | Elevated |
| Q3 2024 | 3.3x | Elevated |
| Q2 2024 | 4.2x | High |
| Q1 2024 | 4.0x | High |
TAK's net debt is about 3.1 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TAK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.9 | Overbought |
| Stochastic | 89.0 | Overbought |
TAK's weekly RSI is 74 (overbought) and its Stochastic is 89 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TAK PE vs Healthcare Sector
| Metric | TAK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TAK has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TAK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.8 | 6.7% above |
| 20 week MA | $18.5 | 14% above |
| 50 week MA | $17.4 | 21% above |
| 100 week MA | $15.9 | 33% above |
| 200 week MA | $15.3 | 38% above |
TAK has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TAK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.8 | $18.1 | -8.7% |
| 2021 | $18.1 | $13.8 | -24% |
| 2022 | $13.8 | $15.5 | +13% |
| 2023 | $15.5 | $14.3 | -8.2% |
| 2024 | $14.3 | $13.3 | -7% |
| 2025 | $13.3 | $15.7 | +18% |
| 2026 YTD | $15.7 | $21.1 | +35% |
TAK has the edge over HIMS on returns for 2026, with the stronger performance.